There has still been no reckoning for the five long months it took for the authorities to warn the public about myocarditis from Covid vaccines, nor for falsely claiming it was only "mild" when they did, says Dr Ros Jones.
The post There Has Been No Reckoning for the Five Months it Took to Warn the Public About Myocarditis From Covid Vaccines appeared first on The Daily Sceptic.
A fourth person in Pennsylvania has died of measles, the state health department confirmed Tuesday. The latest death was in an unvaccinated 18-year-old resident of Mifflin County.
In the announcement, the state health department also confirmed a county coroner's report over the weekend of the death of an unvaccinated 40-year-old woman in Jefferson County. The state had previously reported two deaths in Lancaster County; both were infants—a newborn boy and a 6-week-old girl, both too young to be vaccinated.
According to the Mifflin County coroner, Andrea L. Alcalde, the 18-year-old's cause of death was determined to be acute disseminated encephalomyelitis (ADEM), which is a rare but known severe complication of measles. The condition is characterized by a rapidly progressing autoimmune disorder in which aberrant inflammation from an infection strips away the protective coverings of nerve cells in the brain and spinal cord. Before measles vaccines were widely used, ADEM was commonly associated with measles, though other viral infections can also spur its development.
© Getty | Natalya Maisheva
US Health Secretary Robert F. Kennedy Jr. will deliver a keynote address at an anti-vaccine conference being held in Washington, DC, later this week and hosted by the anti-vaccine organization he once led, Children's Health Defense (CHD). The organization announced Monday that Kennedy had signed on to the event.
Kennedy will appear alongside other high-profile figures in the anti-vaccine world, including Andrew Wakefield, the disgraced former doctor who was stripped of his medical license over a fraudulent, now-retracted study that falsely claimed a link between autism and the measles, mumps, and rubella (MMR) vaccine. An investigation by a medical board found that Wakefield had mistreated vulnerable children and that his actions amounted to serious professional misconduct.
Despite being ostracized from the medical community, Wakefield has become an enduring figure in the anti-vaccine community. His dangerous falsehood that vaccines cause autism has also endured—with significant help from CHD and Kennedy, who have embraced and widely promoted the erroneous link.
© Kevin Dietsch / Staff | Getty Images News
New mRNA jabs could change how vaccines chase viruses.
President Trump signed an executive order Monday that makes sweeping, unilateral changes to federal vaccine recommendations. The order aims to reduce the number of lifesaving vaccines all children are recommended to get—from 18 to 11—while also splitting them up and spacing them out over more time and more medical visits.
The vaccine changes are not backed by evidence or spurred by new findings. Rather, they are based on false anti-vaccine fearmongering about harms, including the debunked claim that they cause autism, and misinformation that multiple vaccinations can "overwhelm" children's immune systems. This false claim has also been repeatedly debunked and explained.
During a signing event at the White House on Monday afternoon, Trump falsely claimed that pediatricians "have a vaccination that looks like the size of a bottle of soda," that is "poured into a little child's body, and bad things happen in too many cases. This is an explosion; this is an epidemic," Trump said.
© Getty | Bonnie Cash
Ebola vaccine research has taken a step toward broader protection against one of the most persistent challenges in filovirus medicine: the existence of multiple Ebola virus species that can cause severe human disease. In a study published in Nature Communications, Weidle, Brunette, Wrenn and colleagues report that a pan-Ebolavirus nanoparticle vaccine protected rodents from lethal infection with both Zaire ebolavirus and Sudan ebolavirus. The finding is significant because vaccines designed around a single viral species may not provide reliable protection against genetically distinct Ebola viruses, particularly those responsible for separate outbreaks in different regions of Africa.
Ebola viruses belong to the filovirus family, a group of filament-shaped, enveloped viruses capable of causing hemorrhagic fever. Zaire ebolavirus is the species most closely associated with the large West African epidemic of 2014–2016 and remains the primary target of licensed Ebola vaccines. Sudan ebolavirus, however, is sufficiently different at the molecular level to present a separate immunological challenge. Outbreaks caused by Sudan virus have repeatedly demonstrated the need for countermeasures that are not limited to one viral lineage. A vaccine capable of recognizing shared features across several Ebola viruses could therefore simplify outbreak preparedness and improve the speed of emergency responses.
The strategy described in the study is based on nanoparticle vaccine technology. Nanoparticles can be engineered to present viral antigens in a highly organized, repetitive arrangement that resembles the dense surface of an actual virus. This geometry can improve the activation of B cells, the immune cells responsible for producing antibodies, by efficiently cross-linking B-cell receptors. Nanoparticles may also enhance the delivery of antigens to lymphoid tissues, where immune responses are initiated and refined. Rather than presenting a soluble protein in a relatively dispersed form, the platform is designed to display Ebola-related molecular targets in a configuration that can stimulate a stronger and more coordinated response.
A central challenge in creating a pan-Ebolavirus vaccine is selecting antigens that are both accessible to the immune system and sufficiently conserved among viral species. Ebola viruses share a broad structural organization, but their surface glycoproteins contain regions that vary in sequence and shape. The glycoprotein is especially important because it enables the virus to attach to host cells and enter them. Antibodies that bind to vulnerable regions of this protein can block infection, interfere with membrane fusion or mark viral particles for destruction by immune cells. A broadly protective vaccine must therefore encourage immunity against sites that remain functionally important even as the virus evolves.
In the rodent experiments, the vaccine was evaluated against lethal challenge with viruses representing the Zaire and Sudan species. Such challenge studies are designed to test whether vaccination-induced immunity can prevent severe disease after exposure to a high-risk pathogen. Protection in this setting reflects the combined activity of several immune mechanisms, including neutralizing antibodies, antibody-dependent cellular functions and virus-specific T-cell responses. Antibodies can prevent viral entry into cells, while T cells and other immune components help eliminate infected cells and limit the spread of infection. The reported protection across both virus species indicates that the nanoparticle formulation generated immune recognition broad enough to cross an important species barrier.
The result does not mean that the viruses are identical, nor does it establish that the vaccine will perform in humans in the same way. Rodent immune systems, dosing schedules and routes of exposure can differ substantially from human conditions. Animal challenge models are nevertheless a crucial stage in vaccine development because they reveal whether an immune response is capable of controlling infection under stringent circumstances. They also allow researchers to examine how quickly protection develops, how long it persists and whether vaccination reduces viral replication and tissue damage. Further studies will be needed to determine which immune markers best predict protection and whether the platform can be adapted for use against additional Ebola species.
The broad scope of the vaccine could have practical implications for epidemic preparedness. Existing Ebola vaccination strategies have demonstrated that immunization can protect against severe disease, but the need to match a vaccine to a particular viral species can complicate decisions during an outbreak. When the causative virus is initially unknown, health authorities may face uncertainty over which product to deploy. A pan-Ebolavirus formulation could potentially reduce that uncertainty by providing coverage against more than one major pathogen. It could also be useful for laboratory personnel, health-care workers and communities living in regions where different Ebola species may emerge over time.
Nanoparticle approaches may offer additional advantages beyond breadth. Their modular design can allow scientists to alter the antigen displayed on the particle without rebuilding the entire vaccine concept from the beginning. This flexibility is relevant to viral pathogens, which can change through mutation and may contain several related species with distinct antigenic profiles. At the same time, the platform must meet demanding standards for manufacturing consistency, stability, storage and safety. A formulation that performs well in laboratory animals must eventually demonstrate reproducible production, acceptable tolerability and durable protection in progressively more advanced models before clinical testing can be considered.
The study’s findings place nanoparticle engineering among the most promising strategies for developing next-generation filovirus vaccines. By combining multivalent antigen presentation with targets shared across Zaire and Sudan viruses, the researchers have demonstrated a route toward broader Ebola protection in rodents. The work does not eliminate the need for species-specific vaccines or replace surveillance, rapid diagnostics and infection-control measures. It does, however, provide experimental evidence that a single vaccine design can generate protective immunity against two medically important Ebola viruses. As outbreaks continue to expose gaps in preparedness, such cross-species technologies could become an important part of the scientific effort to prevent Ebola from turning a local emergence into a global health crisis.
Subject of Research: Pan-Ebolavirus nanoparticle vaccine protection against lethal Zaire and Sudan virus infection in rodents
Article Title: Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses
Article References: Weidle, C., Brunette, N., Wrenn, S.P. et al. Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses. Nature Communications (2026). https://doi.org/10.1038/s41467-026-76114-1
Image Credits: AI Generated
DOI: 10.1038/s41467-026-76114-1
Keywords: Ebola virus, Zaire ebolavirus, Sudan ebolavirus, pan-Ebolavirus vaccine, nanoparticle vaccine, filoviruses, viral immunology, infectious disease, vaccine research, rodent models
The White House is drafting an executive order on the disproven link between vaccines and autism, according to independent reports from The Washington Post and Bloomberg, which both cited unnamed sources with knowledge of the efforts.
Bloomberg reported that the executive order, which is still taking shape and is subject to change, could be issued as soon as next week. The Post said the order's drafting so far is aimed at the childhood vaccine schedule, autism research, and parental choice for vaccinations.
Dozens of high-quality studies encompassing data from millions of children worldwide have already been carried out on the topic and have consistently found no link between childhood vaccines and autism. The claim of a link stems from an unethical, fraudulent study that was retracted years ago, and its author was stripped of his medical license.
© Getty | Tom Brenner
Two nominees for high-profile health roles in the Trump administration faced scrutiny from the Senate health committee Wednesday—and both crashed and burned in their own special ways.
The Senate Committee on Health, Education, Labor, and Pensions (HELP) scrutinized Erica Schwartz, the nominee for director of the Centers for Disease Control and Prevention, and Sean Kaufman, up for the role of assistant secretary for preparedness and response.
Public health experts were "cautiously optimistic" about Schwartz's nomination. She is well-respected and holds views in line with evidence-based medicine, including being supportive of vaccinations—in contrast to anti-vaccine Health Secretary Robert F. Kennedy Jr., whom she will serve under. She is also highly qualified for the role, with a medical degree, a master's degree in public health, and a law degree. She's had a long career as a Navy Officer and previously held the roles of chief medical officer for the US Coast Guard and deputy surgeon general in the first Trump administration.
© Getty | Finn Gomez
Researchers have found that the natural compound spermidine can help improve vaccine responses in older adults by reducing molecular markers of immune system aging. A vaccine shot can look the same from one arm to the next, but the immune system beneath the skin may not respond with the same force. In older adults, that [...]
Scientists have uncovered a shared target used by multiple diarrhea-causing bacteria to invade the gut. Despite decades of research, scientists still do not have vaccines against two of the world’s most common causes of severe bacterial diarrhea: enterotoxigenic E. coli (ETEC) and Shigella. Together, these pathogens infect hundreds of millions of people each year and [...]
Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna's seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to block from even being reviewed.
In an all-day meeting, members of the FDA's advisory committee—known as VRBPAC for Vaccines and Related Biological Products Advisory Committee—pored over data and presentations on the vaccine, which is dubbed mRNA-1010 and branded as mFlusiva. The presentations included a review from FDA scientists, which was supportive of the vaccine.
Data from a Phase 3 trial including over 40,000 adults age 50 and older found the mRNA vaccine was around 27 percent more effective against seasonal flu than a standard flu shot. A smaller Phase 3 trial, involving data from nearly 3,000 people age 65 years and older, showed the shot produces stronger immune responses than a high-dose flu vaccine, which is recommended for this age group. The safety profile of the vaccine was also generally good.
© DeFodi Images
An experimental vaccine could help stop fentanyl and future designer-drug variants before they can trigger a deadly overdose. Fentanyl has become one of the deadliest drugs in the United States, with fentanyl and related synthetic opioid variants now claiming more lives each year than car crashes and gun violence combined. When taken in excessive amounts, [...]
University of California, Irvine Innovates Therapeutic Vaccine Strategy to Combat Recurrent Genital Herpes
In a groundbreaking development that could transform the management of genital herpes, UC Irvine immunologist Lbachir BenMohamed has secured nearly $4 million in funding from the National Institutes of Health to advance a novel therapeutic vaccine approach. This ambitious five-year project aims to tackle recurrent genital herpes caused by herpes simplex virus type 2 (HSV-2), a persistent viral infection that affects over 60 million Americans and more than half a billion individuals globally. Despite extensive research efforts historically, no approved therapeutic vaccine exists to date, leaving millions vulnerable to recurrent outbreaks and transmission.
BenMohamed’s research focuses on a next-generation vaccine strategy termed “Prime/Pull/Keep,” designed to establish a robust, localized immune defense precisely at the mucosal sites where HSV-2 resides and reactivates. Conventional vaccines predominantly elicit circulating antibodies, which are insufficient to control HSV-2’s latent reservoirs in the nerve ganglia and mucosal tissues. This innovative approach instead targets tissue-resident memory T cells (TRM), a specialized subset of immune cells critically positioned at the barrier sites to provide immediate defense against viral reactivation.
The Prime/Pull/Keep methodology encompasses a three-step immunization process: initial priming of protective T cells via vaccination, mobilization of these cells to the infected tissue through chemokine signals (pull), and sustained retention and functional maintenance at the site of infection (keep). Together, these steps ensure a sustained population of antiviral T cells, capable of rapid detection and elimination of reactivated virus, potentially curbing recurrent disease manifestations and viral shedding.
Previous investigations by BenMohamed’s team have demonstrated promising results with mRNA-based therapeutic vaccines in preclinical models. These candidates were effective in reducing clinical signs of recurrent genital herpes and enhancing the recruitment of protective T cells within genital mucosal tissues. Additionally, exploring immune-signaling molecules such as chemokines has validated the feasibility of attracting and retaining TRM populations, thereby improving local immune surveillance and long-term antiviral immunity.
The current NIH-funded project intends to rigorously evaluate the safety profile and immunogenic potential of various Prime/Pull/Keep vaccine candidates in preclinical animal models, examining how augmenting the quantity, quality, and durability of TRM cells correlates with protection from HSV-2 reactivation. This represents a critical translational step toward bridging laboratory research and clinical trials, responding to NIH’s strategic priority to develop novel therapeutic interventions for genital herpes.
BenMohamed articulates the significance of this research succinctly: “People living with recurrent genital herpes have long awaited effective therapeutic vaccines. Our innovative immune-based approach not only amplifies protective T cells but directs and maintains them where the virus hides. This could revolutionize prevention strategies for millions affected worldwide.” The team’s vision is to develop a vaccine capable of reducing recurrent outbreaks and viral transmission, substantially improving quality of life for patients.
HSV-2 represents a formidable pathogen due to its ability to establish lifelong latent infection in sensory neurons, periodically reactivating to cause painful genital lesions and facilitating onward transmission. Existing antiviral therapies focus on suppressing viral replication but do not eliminate reservoirs or prevent recurrence. The targeted boosting of tissue-resident immune memory represents a paradigm shift in immunotherapy, promising durable tissue-specific immunity where it is needed most.
The Prime/Pull/Keep vaccination strategy could also circumvent issues faced by traditional systemic vaccines, which often fail to generate sufficient mucosal immunity or induce long-lasting memory T cell populations within genital tissues. By tailoring antigen delivery and immune modulation, this approach aims to enhance the local microenvironment and foster a self-renewing population of sentinel T cells poised to respond immediately to viral reactivation.
As the project advances through preclinical stages, rigorous assessment of immune correlates of protection will inform optimization of vaccine formulations, dosing schedules, and adjuvant combinations. Understanding the mechanisms underpinning TRM cell maintenance and functionality remains an active area of investigation critical to maximizing therapeutic efficacy and durability.
The successful identification of an optimal Prime/Pull/Keep candidate would pave the way for human clinical trials, marking a historic milestone in the fight against genital herpes. Such a vaccine holds the promise not only to alleviate recurrent symptoms but also to significantly curtail viral shedding, thereby decreasing transmission rates and public health burden.
Beyond genital herpes, the conceptual framework underlying Prime/Pull/Keep may inspire novel immunotherapeutic strategies for other persistent viral infections and chronic diseases where localized immune memory is pivotal. Collaborative efforts among immunologists, virologists, and clinical scientists will be essential to translate these findings into effective interventions.
With UC Irvine’s robust infrastructure, cutting-edge facilities, and interdisciplinary expertise, BenMohamed’s laboratory is well-positioned to spearhead this transformative endeavor. The $3.93 million NIH R01 grant underscores the scientific community’s confidence in this pioneering approach and its potential to redefine therapeutic vaccine development for chronic viral infections.
In conclusion, the UC Irvine-led Prime/Pull/Keep vaccine project represents a beacon of hope for millions plagued by recurrent genital herpes, offering a sophisticated and strategic means to harness the immune system’s power at the precise sites of viral latency and reactivation. As research progresses, the scientific world eagerly anticipates the realization of a durable, tissue-targeted therapeutic vaccine capable of changing the landscape of HSV-2 management and prevention.
Subject of Research: Development of a novel therapeutic vaccine to prevent recurrent genital herpes by targeting tissue-resident memory T cells
Article Title: UC Irvine Advances Prime/Pull/Keep Therapeutic Vaccine Strategy to Combat Recurrent Genital Herpes
News Publication Date: June 16, 2026
Web References:
– University of California, Irvine: www.uci.edu
– UC Irvine News: news.uci.edu
– NIH Media Resources: https://news.uci.edu/media-resources/
Keywords: herpes simplex virus type 2, HSV-2, genital herpes, therapeutic vaccine, tissue-resident memory T cells, Prime/Pull/Keep, immunotherapy, mRNA vaccine, viral latency, NIH funding, recurrent infections, mucosal immunity
A new nanodisc breakthrough lets scientists see viruses more realistically, revealing hidden clues that could lead to better vaccines. Viruses are highly effective at infecting human cells, largely because of specialized proteins that cover their outer surfaces. These proteins are also a key focus for vaccine design. To study them, scientists often create lab-made versions [...]
A groundbreaking AI-designed vaccine aims to protect against not only today’s coronaviruses, but tomorrow’s as well. A new type of universal coronavirus vaccine has passed its first test in humans, marking an important step toward broader protection against future viral threats. Researchers from the University of Cambridge and biotechnology company DIOSynVax (DVX) Ltd reported that [...]
An early human trial suggests a new vaccine strategy is safe, but still not proven effective.
Login